Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies

Kazuyuki Mizuno, Takanori Ito, Masatoshi Ishigami, Yoji Ishizu, Teiji Kuzuya, Takashi Honda, Hiroki Kawashima, Yosuke Inukai, Hidenori Toyoda, Kenji Yokota, Tetsunari Hase, Osamu Maeda, Hitoshi Kiyoi, Masato Nagino, Hideharu Hibi, Yasuhiro Kodera, Yasushi Fujimoto, Michihiko Sone, Momokazu Gotoh, Yuichi AndoMasashi Akiyama, Yoshinori Hasegawa, Mitsuhiro Fujishiro

研究成果: Article査読

19 被引用数 (Scopus)

抄録

Background: Liver injury induced by immune checkpoint inhibitors (ICIs) is an immune-related adverse event (irAE) whose incidence has increased with the broader use of ICIs in clinical practice. However, the incidental risk factors of immune-related liver injury are unknown. We investigated the clinical characteristics of immune-related liver injury. Methods: A total of 546 patients treated with ICIs for advanced malignancies between September 2014 and February 2019 were included retrospectively. Factors associated with immune-related liver injury were determined. Results: Immune-related liver injury (≥ Grade 3) occurred in 29 (5.3%) patients (Grade 3, n = 20; Grade 4, n = 8; Grade 5, n = 1) during the follow-up period (median 153 days). The patterns of liver injuries were hepatocellular, n = 6 (20.7%); cholestatic, n = 17 (58.6%); and mixed, n = 6 (20.7%). The median period between the initial administration of ICIs and the incidence of irAEs was 52 days. Of 29 patients with immune-related liver injury (≥ Grade 3), four showed immune-related cholangitis with non-obstructive dilation of the bile ducts. Factors that were significantly associated with the incidence of immune-related liver injury in multivariate analysis were use of ipilimumab, anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) agent [hazard ratio [HR] 4.22, 95% confidence interval (CI) 1.65–10.80, P = 0.003], and fever over 38 °C within 24 h of initial ICI administration (HR 6.21, 95% CI 2.68–14.40, P < 0.001). Conclusions: We found that the use of ipilimumab and the presence of fever within 24 h of initial ICI administration were predictive factors for immune-related liver injury.

本文言語English
ページ(範囲)653-661
ページ数9
ジャーナルJournal of Gastroenterology
55
6
DOI
出版ステータスPublished - 01-06-2020
外部発表はい

All Science Journal Classification (ASJC) codes

  • 消化器病学

フィンガープリント

「Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル